Iovance Biotherapeutics, Inc.'s Amtagvi has been approved but what is next for TIL Therapies? Join us this October at the 6th Annual TIL Therapies Summit to expand TIL treatment beyond melanoma. In our agenda you will find: 🗣 KSQ Therapeutics, Inc.'s discussion on KSQ-001EX which was recently dosed in the first patient. 💊 Iovance Biotherapeutics, Inc.'s presentation on their next generation TIL candidates. 💰 Alliance for Regenerative Medicine's panel discussion on preparing TIL treatment for commercialization. 📈 Marble Therapeutics's talk on current innovations in cell culture methods for effective TIL expansion. Discover the full session descriptions ➡ https://ter.li/zi4url With brand-new 2 tracked agenda, this summit will provide your entire team with the cutting-edge insights and tools needed to streamline manufacturing, enhance product potency, and optimize patient treatment! Secure your pass ➡ https://ter.li/xk9w4s
Hanson Wade Group’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> AstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech
-
The global pet cancer therapeutics market size is expected to grow from $0.31 billion in 2022 to $0.35 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. https://lnkd.in/gh63chYH #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel
-
-
Outreach @ 23andMe | Health strategist & builder | Genomics & policy champion | Clinical expert & speaker | Ex-Hopkins, ex-JunoDx
Attending #ASCO24 in Chicago this week? 🔬 Be sure to check out the 23andMe Therapeutics team's work related to 23ME-00610, a first-in-class anti-CD200R1 monoclonal antibody in the Phase 2a portion of Phase 1/2a clinical development for advanced solid malignancies. ⚡ Cancer therapeutics, precision medicine, precision oncology, drug development, genomic medicine
Meet the 23andMe Therapeutics team at #ASCO24 next week! We look forward to sharing preliminary efficacy and biomarker data for our lead investigational, first-in-class antibody 23ME-00610 in the treatment of multiple advanced solid tumors. https://lnkd.in/gY5ECQ6R #ASCO24
-
-
Thoughts on this? >> AstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare
AstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial
https://endpts.com
-
Looking for a suitable in vivo #efficacy model to accelerate 🚀 your anticancer development? 👉Tap into our broad experience in #oncology efficacy studies for NCEs, biologics, and cell-based therapies. Our customized services meet your needs at every phase of your drug development journey. 👉Explore our extensive platform of in vivo tumor models and over 100 human cancer cell lines. Take advantage of our #orthotopic and #bioluminescent models for more effective and close-to-human tumor growth evaluation. Stay ahead with our #syngeneic, #humanized, and immunotherapy-tailored mouse models. 🔗Partner with Accelera for robust efficacy assessments and unlock the future of drug development today! ✉Contact our experts at [email protected] accelera.org #DrugEfficacy #DrugDevelopment #AnticancerDrug #NCE #biologics #cellbasedtherapy #CRO #nonclinical
-
-
Precision Medicine + Free Chemotherapy Side Effects + Broad-Spectrum : Antican Offers an Innovative Anti-Cancer Hope Patients: Dream of effective anti-cancer drugs with no side effects. Investors & Pharma: Seeking new drugs with broader range of indications, benefiting more patients. "Broad-Spectrum + Precision Medicine + Free Chemotherapy Side Effects Anti-Cancer New Drug" is eagerly awaited by everyone! Meeting patient needs is the most critical core. I invite you to contact / message me. Your support to create new hope for cancer patients is important. # Broad-Spectrum # Precision Medicine # Free Chemotherapy Side Effects # Anti-Cancer New Drug # Antican # Hope
-
-
Alligator Bioscience AB announced positive top-line results from the OPTIMIZE-1 Phase II trial in pancreatic cancer, revealing that mitazalimab combined with mFOLFIRINOX achieved a 40.4% overall response rate (ORR), a median duration of response (DoR) of 12.5 months, and a median overall survival (mOS) of 14.3 months. This compares favorably to the 11.1 months mOS seen with first-line chemotherapies FOLFIRINOX and NALIFIROX. With more than half of the patients still in the study at the primary analysis, the 18-month survival follow-up data was presented at American Society of Clinical Oncology (ASCO) 2024. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: https://lnkd.in/gZDPhuxR #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders
Mitazalimab OPTIMIZE-1 Trial | ASCO 2024
delveinsight.com
-
Scientist Associate Junior | Toxicology and DART Study Director | Safety Preclinical Development
Ready to dive into your anticancer efficacy assessment? Accelera - Part of NMS Group has the models and expertise to get your drug molecule moving forward 🚀
Looking for a suitable in vivo #efficacy model to accelerate 🚀 your anticancer development? 👉Tap into our broad experience in #oncology efficacy studies for NCEs, biologics, and cell-based therapies. Our customized services meet your needs at every phase of your drug development journey. 👉Explore our extensive platform of in vivo tumor models and over 100 human cancer cell lines. Take advantage of our #orthotopic and #bioluminescent models for more effective and close-to-human tumor growth evaluation. Stay ahead with our #syngeneic, #humanized, and immunotherapy-tailored mouse models. 🔗Partner with Accelera for robust efficacy assessments and unlock the future of drug development today! ✉Contact our experts at [email protected] accelera.org #DrugEfficacy #DrugDevelopment #AnticancerDrug #NCE #biologics #cellbasedtherapy #CRO #nonclinical
-
-
Gilead stops recruitment in CD47 solid tumor trials, a week after it axed blood cancer development >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #productmarketing #pharmaceutical
Gilead stops recruitment in CD47 solid tumor trials, weeks after it axed blood cancer development
https://endpts.com
-
The #oncology #radiopharmaceutical market is advancing rapidly, with several key players vying for market share. IQVIA's experience and expertise reshape trial pipeline to overcome complexities and executive development process in phase I - IV. Read the fact sheet to learn more: https://bit.ly/4eFQJrq #Radiotherapy #Radiooncology
-
